



Social Media Toolkit

2025 U.S. Generic & Biosimilar Medicines Savings Report

Generic and biosimilar medicines saved America's patients and the U.S. healthcare system \$467 billion in 2024. But future savings through the use of lower-cost generics and biosimilars are in peril. In fact, the long-term outlook for generic and biosimilar medicines hinges on addressing barriers to development and adoption, and the overarching sustainability of this vital industry—so vital, it allows for 90 percent of all prescriptions written in the U.S. to be filled.

Without purposeful action from U.S. policymakers, the lower-cost medicines America's patients depend on may disappear. **Please utilize this social media toolkit.** Post on your social media channel and tag [@accessiblemeds](#) and [@biosimilarscouncil](#). Doing so will help spread the word on the importance of a healthy generic and biosimilar medicines industry, ensuring patients across the U.S. have access to the medicines they need to thrive!

#GRxBiosimsSavingsReport

The 2025 Savings Report

- AAM Website: accessiblemeds.org
- AAM Report Page: <https://accessiblemeds.org/resources/blog/2025-savings-report>
- Biosimilars Council Website: biosimilarscouncil.org
- Biosimilars Council Report Page: <https://biosimilarscouncil.org/resource/2025-generic-biosimilar-medicines-savings-report>

Follow AAM



Follow Biosimilars Council



Help Spread the Word

We encourage you to utilize the info in this toolkit to help raise awareness around the benefit of generic and biosimilar medicines—as well as the impact policy and regulatory decisions can have on the sustainability of this essential industry. Please post on any or all of your favorite social media channels and please include the hashtag [#GRxBiosimsSavingsReport](#). Please also consider tagging [@accessiblemeds](#) and [@biosimscouncil](#) – so we can share your message on our channels, too!

Social-Ready Graphics

Download all images [here](#) 

Hashtags


[#GRxBiosimsSavingsReport](#)

[#Generics](#)


[#GenericMedicines](#)

[#Biosimilars](#)


Questions? Please email the AAM Communications Department at: media@accessiblemeds.org




In the past decade, [#generic](#) and [#biosimilar](#) medicines have saved the U.S. healthcare system \$3.4 trillion. Still, threats to the sustainability of this essential industry remain. Policymakers must ACT NOW to streamline FDA processes, curb patent abuse, stop PBMs and Medicare policies from denying patient access, and rollback harmful federal policies – including IRA price controls – to safeguard the livelihood of America’s patients. Learn more in the [#GRxBiosimsSavingsReport](#): <https://accessiblemeds.org/resources/blog/2025-savings-report>




A decade after the first biosimilar entered to the U.S. market, \$56.2 billion have been saved by the healthcare system and 3.3 billion additional days of patient care have been possible. But due to harmful policies that impeded biosimilar uptake, we are currently experiencing a biosimilar void. Policymakers must ACT NOW to safeguard enormous benefits to Americans—\$20.2 billion in 2024, alone. MORE: <https://accessiblemeds.org/resources/blog/2025-savings-report> [#GRxBiosimsSavingsReport](#)




In 2024, [#generics](#) & [#biosimilars](#) saved America’s patients and the U.S. healthcare system \$467 billion—and \$3.4 trillion in the past 10 years. Learn more, including what can be done to help safeguard this important industry: <https://accessiblemeds.org/resources/blog/2025-savings-report> [#GRxBiosimsSavingsReport](#)




Generic medicines give America’s patients the confidence to thrive! Last year, [#generics](#) comprised 90% of all prescriptions filled, but only 12% of prescription spending. In sharp contrast, brand drugs supported patients less often— making up only 10% of prescriptions filled but adding up to 88% of the total drug spend. Learn more about what makes generic medicines unique in AAM’s [#GRxBiosimsSavingsReport](#): <https://accessiblemeds.org/resources/blog/2025-savings-report>




Comprising only 1.2 percent of total U.S. healthcare spending in 2024, generic medicines saved American's \$467 billion—providing patients the health and financial outcomes necessary to thrive. <https://accessiblemeds.org/resources/blog/2025-savings-report> #GRxBiosimsSavingsReport




Right now, little is being done to infuse sustainability into the generic marketplace. Compared to 30 years ago, generic drugs are launching at lower prices and bottoming out at lower prices. This generic deflation puts savings and America's patients in jeopardy. Learn what can be done to help safeguard the savings for patients AND help strengthen the industry: <https://accessiblemeds.org/resources/blog/2025-savings-report> #GRxBiosimsSavingsReport




The average market entry of a first generic is between 12 and 14 years; and approximately 18 years for a first biosimilar. One thing is clear: The Inflation Reduction Act (IRA) harms generic and biosimilar medicine competition and it must be amended— especially to promote more robust biosimilar competition. <https://accessiblemeds.org/resources/blog/2025-savings-report> #GRxBiosimsSavingsReport




#Generics and #biosimilars provide critical savings throughout the U.S. healthcare system and are particularly valuable to Medicare and the patients they serve. In 2024, the use of generics saved \$142 billion in Medicare and \$62 billion in Medicaid. Learn more about savings from this essential industry and what can be done to ensure America's patients can thrive with access to these lower-cost medications: #GRxBiosimsSavingsReport: <https://accessiblemeds.org/resources/blog/2025-savings-report>



PBM DELAY PATIENT SAVINGS! First generics, or medicines approved by FDA as the first competitor to the brand drug, often face challenges in market adoption. Slower adoption for first generics is driven in part by slower coverage decisions of PBMs and health plans. These entities benefit from rebates on high-priced brand drugs, even though patients would save through lower-cost generics and biosimilars. Learn more: <https://accessiblemeds.org/resources/blog/2025-savings-report> #GRxBiosimsSavingsReport



DRUG SHORTAGES HAMPER PATIENT CARE!
Continued #generic drug shortages are a result of unsustainably low pricing, increases in government policies – including tariffs – that further compound market dynamics, and regulatory challenges. Learn more in the #GRxBiosimsSavingsReport: <https://accessiblemeds.org/resources/blog/2025-savings-report>



Over the next decade, 118 biologics are expected to lose patent exclusivity, presenting a \$234 billion opportunity for biosimilars in the U.S. But of these 118 biologics, only 12 molecules currently have biosimilars in development. Closing this biosimilar void requires coordinated action across an entire ecosystem of stakeholders – manufacturers, providers, payers, and policymakers. Learn more on what needs to change: <https://accessiblemeds.org/resources/blog/2025-savings-report> #GRxBiosimsSavingsReport



accessiblemeds.org



biosimilarscouncil.org